Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis
Purpose: To evaluate the safety and efficacy of remdesivir in adult patients with COVID-19. Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov, and medRxiv databases were searched using a search strategy tailored to each database. The Consolidated Standards of Repo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Journal of Pharmacy & Pharmaceutical Sciences |
| Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31870 |
| _version_ | 1797717886652907520 |
|---|---|
| author | Mohammad Tasavon Gholamhoseini Vahid Yazdi-Feyzabadi Reza Goudarzi Mohammad Hossein Mehrolhassani |
| author_facet | Mohammad Tasavon Gholamhoseini Vahid Yazdi-Feyzabadi Reza Goudarzi Mohammad Hossein Mehrolhassani |
| author_sort | Mohammad Tasavon Gholamhoseini |
| collection | DOAJ |
| description | Purpose: To evaluate the safety and efficacy of remdesivir in adult patients with COVID-19. Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov, and medRxiv databases were searched using a search strategy tailored to each database. The Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the reporting of observational studies in epidemiology (STROBE) checklists were used for the studies' qualitative assessment. The outcomes studied were mortality, all adverse events, serious adverse events, and clinical improvement. The quantitative synthesis was conducted using fixed and random effects models in the CMA 2.2. Heterogeneity was tested using the I-squared (I2) measure. Results: In general, six studies, including five randomized controlled trials and one cohort study were found eligible. Comparison of the findings related to both groups receiving remdesivir (10-day remdesivir group) and placebo/control group showed that remdesivir treatment had no significant effect on mortality at day 14 of the treatment (RR=0.769; 95% CI :0.563-1.050; p=0.098), and all adverse events (RR= 1.078; 95% CI: 0.908-1.279; p= 0.392). However, remdesivir had a significant effect on clinical improvement at day 14 compared to placebo/control (OR= 1.447; 95% CI: 1.005-2.085; p= 0.047) and reduced serious adverse events (RR= 0.736; 95% CI: 0.611-0.887; p= 0.001). Conclusion: Remdesivir has positive effects on clinical improvement, and reduction of the risk of serious adverse events. However, it does not influence the mortality at day 14 of treatment. |
| first_indexed | 2024-03-12T08:42:56Z |
| format | Article |
| id | doaj.art-70a0d245b8414117ac9d3cf0784f7c63 |
| institution | Directory Open Access Journal |
| issn | 1482-1826 |
| language | English |
| last_indexed | 2024-03-12T08:42:56Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Pharmacy & Pharmaceutical Sciences |
| spelling | doaj.art-70a0d245b8414117ac9d3cf0784f7c632023-09-02T16:36:23ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262021-05-012410.18433/jpps31870Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-AnalysisMohammad Tasavon Gholamhoseini0Vahid Yazdi-Feyzabadi1Reza Goudarzi2Mohammad Hossein Mehrolhassani3Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, IranHealth in Disasters and Emergencies Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, IranHealth Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, IranSocial Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran Purpose: To evaluate the safety and efficacy of remdesivir in adult patients with COVID-19. Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov, and medRxiv databases were searched using a search strategy tailored to each database. The Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the reporting of observational studies in epidemiology (STROBE) checklists were used for the studies' qualitative assessment. The outcomes studied were mortality, all adverse events, serious adverse events, and clinical improvement. The quantitative synthesis was conducted using fixed and random effects models in the CMA 2.2. Heterogeneity was tested using the I-squared (I2) measure. Results: In general, six studies, including five randomized controlled trials and one cohort study were found eligible. Comparison of the findings related to both groups receiving remdesivir (10-day remdesivir group) and placebo/control group showed that remdesivir treatment had no significant effect on mortality at day 14 of the treatment (RR=0.769; 95% CI :0.563-1.050; p=0.098), and all adverse events (RR= 1.078; 95% CI: 0.908-1.279; p= 0.392). However, remdesivir had a significant effect on clinical improvement at day 14 compared to placebo/control (OR= 1.447; 95% CI: 1.005-2.085; p= 0.047) and reduced serious adverse events (RR= 0.736; 95% CI: 0.611-0.887; p= 0.001). Conclusion: Remdesivir has positive effects on clinical improvement, and reduction of the risk of serious adverse events. However, it does not influence the mortality at day 14 of treatment.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31870 |
| spellingShingle | Mohammad Tasavon Gholamhoseini Vahid Yazdi-Feyzabadi Reza Goudarzi Mohammad Hossein Mehrolhassani Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis Journal of Pharmacy & Pharmaceutical Sciences |
| title | Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |
| title_full | Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |
| title_fullStr | Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |
| title_short | Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |
| title_sort | safety and efficacy of remdesivir for the treatment of covid 19 a systematic review and meta analysis |
| url | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31870 |
| work_keys_str_mv | AT mohammadtasavongholamhoseini safetyandefficacyofremdesivirforthetreatmentofcovid19asystematicreviewandmetaanalysis AT vahidyazdifeyzabadi safetyandefficacyofremdesivirforthetreatmentofcovid19asystematicreviewandmetaanalysis AT rezagoudarzi safetyandefficacyofremdesivirforthetreatmentofcovid19asystematicreviewandmetaanalysis AT mohammadhosseinmehrolhassani safetyandefficacyofremdesivirforthetreatmentofcovid19asystematicreviewandmetaanalysis |